Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating Expenses:        
Research and development expenses $ 1,243,556 $ 1,691,688 $ 3,040,024 $ 6,062,360
General and administrative expenses 1,944,137 2,371,840 7,037,085 7,245,227
Total Operating Expenses 3,187,693 4,063,528 10,077,109 13,307,587
Loss From Operations (3,187,693) (4,063,528) (10,077,109) (13,307,587)
Other Income (Expense)        
Interest income 3,343 2,862 15,388 4,338
Change in value of contingent liability 75,000 (274,524) 197,000 (335,727)
Other income 17,406 46,494
Total other income (expense) 78,343 (254,256) 212,388 (284,895)
Loss Before Provision For Income Taxes (3,109,350) (4,317,784) (9,864,721) (13,592,482)
Provision for income taxes
Net Loss $ (3,109,350) $ (4,317,784) $ (9,864,721) $ (13,592,482)
Net loss per share, basic and diluted (in Dollars per share) $ (0.12) $ (0.22) $ (0.4) $ (0.76)
Weighted average shares, basic and diluted (in Shares) 25,724,557 19,848,108 24,803,909 17,864,604